NSF award 2625652 · University of Massachusetts Amherst

FDT-BioTech: Theranostic Digital Twins for Personalized Cancer Treatment

Final report due

28 February 2030

in 1,229 days · The award ends on 31 October 2029.

GrantClerk is a private service. We are not NSF or any government agency.

Dates this award owes

NSF emails you about this too.

Decide about an extension3 Jul 2029in 989 days
award ending 2029-10-31 · Research.gov
This one is ours, not NSF’s.
Extension request16 Sep 2029in 1064 days
award ending 2029-10-31 · Research.gov
PAPPG 24-1: “at least 45 days prior to the end date”
No-cost extension notice21 Oct 2029in 1099 days
award ending 2029-10-31 · Research.gov
PAPPG 24-1: “at least ten calendar days prior to the end date”
Final report due28 Feb 2030in 1229 days
award ending 2029-10-31 · Research.gov
PAPPG 24-1: “no later than 120-days following the end date of the award”
Project outcomes report due28 Feb 2030in 1229 days
award ending 2029-10-31 · Research.gov
PAPPG 24-1: “no later than 120 days following the end date”
Award is closed out28 Feb 2030in 1229 days
award ending 2029-10-31 · Research.gov
PAPPG 24-1: “financially closed out 120 days after their expiration date”

Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.

How we got this date

NSF lists this award's end date as 31 October 2029.
NSF rules say the final report is due no later than 120 days after that.
So the final report is due by 28 February 2030.

Read the rule on Research.gov

Get a note before each report date

Add this award to your desk. We email you before each date and keep the dates in one place.

Renews each year until you cancel. Cancel any time from your account.

Already a member? Sign in

Award card

Award number: 2625652
Period of support: 1 Nov 2026 – 31 Oct 2029
Amount: $558,159
Awardee: University of Massachusetts Amherst, Amherst, MA
Program: MSPA-INTERDISCIPLINARY
Directorate: MPS

Abstract

Radiopharmaceutical therapy (RPT) is a new targeted approach to treating cancer that carries radiation directly to cancer cells while sparing the patient’s healthy organs. The RPT drug Pluvicto, approved by the FDA in 2022 for men with metastatic prostate cancer, is now a widely used prostate cancer treatment shown to extend patients’ lives. Every patient today, however, receives the same, fixed RPT injection dosage…

Is this right?

We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.